148 related articles for article (PubMed ID: 38285876)
1. Cellular origin and molecular mechanisms of lung metastases in patients with aggressive hepatoblastoma.
Gulati R; Lutz M; Hanlon M; Cast A; Karns R; Geller J; Bondoc A; Tiao G; Timchenko L; Timchenko NA
Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285876
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation-Mediated Activation of β-Catenin-TCF4-CEGRs/ALCDs Pathway Is an Essential Event in Development of Aggressive Hepatoblastoma.
Gulati R; Hanlon MA; Lutz M; Quitmeyer T; Geller J; Tiao G; Timchenko L; Timchenko N
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551548
[TBL] [Abstract][Full Text] [Related]
3. Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models.
Johnston ME; Rivas MP; Nicolle D; Gorse A; Gulati R; Kumbaji M; Weirauch MT; Bondoc A; Cairo S; Geller J; Tiao G; Timchenko N
Hepatology; 2021 Oct; 74(4):2201-2215. PubMed ID: 34037269
[TBL] [Abstract][Full Text] [Related]
4. C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer.
Cast A; Valanejad L; Wright M; Nguyen P; Gupta A; Zhu L; Shin S; Timchenko N
Hepatology; 2018 May; 67(5):1857-1871. PubMed ID: 29159818
[TBL] [Abstract][Full Text] [Related]
5. Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma.
Ranganathan S; Ningappa M; Ashokkumar C; Higgs BW; Min J; Sun Q; Schmitt L; Subramaniam S; Hakonarson H; Sindhi R
Sci Rep; 2016 Dec; 6():38347. PubMed ID: 27910913
[TBL] [Abstract][Full Text] [Related]
6. FXR-Gankyrin axis is involved in development of pediatric liver cancer.
Valanejad L; Lewis K; Wright M; Jiang Y; D'Souza A; Karns R; Sheridan R; Gupta A; Bove K; Witte D; Geller J; Tiao G; Nelson DL; Timchenko L; Timchenko N
Carcinogenesis; 2017 Jul; 38(7):738-747. PubMed ID: 28535186
[TBL] [Abstract][Full Text] [Related]
7. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
9. HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer.
Rivas M; Johnston ME; Gulati R; Kumbaji M; Margues Aguiar TF; Timchenko L; Krepischi A; Shin S; Bondoc A; Tiao G; Geller J; Timchenko N
Cell Mol Gastroenterol Hepatol; 2021; 12(5):1669-1682. PubMed ID: 34245919
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.
Yamaoka H; Ohtsu K; Sueda T; Yokoyama T; Hiyama E
Oncol Rep; 2006 Mar; 15(3):551-6. PubMed ID: 16465411
[TBL] [Abstract][Full Text] [Related]
11. PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma.
Valanejad L; Cast A; Wright M; Bissig KD; Karns R; Weirauch MT; Timchenko N
Commun Biol; 2018; 1():67. PubMed ID: 30271949
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
13. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.
Takayasu H; Horie H; Hiyama E; Matsunaga T; Hayashi Y; Watanabe Y; Suita S; Kaneko M; Sasaki F; Hashizume K; Ozaki T; Furuuchi K; Tada M; Ohnuma N; Nakagawara A
Clin Cancer Res; 2001 Apr; 7(4):901-8. PubMed ID: 11309340
[TBL] [Abstract][Full Text] [Related]
14. Molecular signatures of aggressive pediatric liver cancer.
Johnston ME; Timchenko N
Arch Stem Cell Ther; 2021; 2(1):1-4. PubMed ID: 34447970
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
17. Novel Advances in Understanding of Molecular Pathogenesis of Hepatoblastoma: A Wnt/β-Catenin Perspective.
Bell D; Ranganathan S; Tao J; Monga SP
Gene Expr; 2017 Feb; 17(2):141-154. PubMed ID: 27938502
[TBL] [Abstract][Full Text] [Related]
18. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
19. HGF/c-Met related activation of β-catenin in hepatoblastoma.
Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Sullivan M
J Exp Clin Cancer Res; 2011 Oct; 30(1):96. PubMed ID: 21992464
[TBL] [Abstract][Full Text] [Related]
20. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
